Drug Profile
NPT 189
Alternative Names: NPT189Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Proclara Biosciences
- Class Antidementias; Antiparkinsonians; Immunoglobulin fusion proteins; Neuroprotectants
- Mechanism of Action Alpha-synuclein inhibitors; Amyloid fibril protein AL inhibitors; Prealbumin inhibitors; Protein aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyloidosis; Parkinson's disease
Most Recent Events
- 28 Dec 2023 Discontinued - Phase-I for Amyloidosis (In volunteers) in Netherlands (IV) before December 2023
- 28 Dec 2023 Discontinued - Preclinical for Parkinson's disease in USA (unspecified route) before December 2023
- 28 Aug 2021 No recent reports of development identified for phase-I development in Amyloidosis(In volunteers) in Netherlands (IV, Infusion)